Shanghai Cell Therapy Group Co., a Chinese biotech company, has completed an RMB925 million (US$135.71 million) series C round of financing, led by China Pacific Insurance Company, Haier Capital and China Industrial Asset Management Limited, according to an announcement yesterday. The round also saw the participation from existing investor Legend Capital, a private equity and venture […]

Legend-Backed Immunotherapy Firm Shanghai Cell Therapy Group Co. Secures $136M Series C Round appeared first on China Money Network.